X
Pharma Advancement
  • Home
  • Drug Development
    • All
    • Clinical Trials
    • FDA Approvals
    • Research & Development

    NHS Acquires Potentially Lifesaving Breast Cancer Medication

    Transfusion of The First Patients Lab-Grown Blood Cells

    Bispecific Cancer Drugs, Gene Therapy Advances At Next ASH

    First Virtual Drug Study Tests 2 Likely Alzheimer Therapies

    First Virtual Drug Study Tests 2 Likely Alzheimer Therapies

    $2 Million Gene Therapy Might Become The Standard In The US

    $2 Million Gene Therapy Might Become The Standard In The US

    Cancer Medicine Prices Jump 53% In Five Years In The U.S

    Food And Drug Administration User Fee Has Been Reauthorized

    Cancer Clinical Trials Get A Brand New Platform In Melbourne

    Report Indicates UK £62bn Behind In Global R&D Investment

    Report Indicates UK £62bn Behind In Global R&D Investment

  • Manufacturing
  • Supply Chain
  • Facilities
  • Health & Nutrition
  • Events
  • Contact Us
No Result
View All Result
  • Home
  • Drug Development
    • All
    • Clinical Trials
    • FDA Approvals
    • Research & Development

    NHS Acquires Potentially Lifesaving Breast Cancer Medication

    Transfusion of The First Patients Lab-Grown Blood Cells

    Bispecific Cancer Drugs, Gene Therapy Advances At Next ASH

    First Virtual Drug Study Tests 2 Likely Alzheimer Therapies

    First Virtual Drug Study Tests 2 Likely Alzheimer Therapies

    $2 Million Gene Therapy Might Become The Standard In The US

    $2 Million Gene Therapy Might Become The Standard In The US

    Cancer Medicine Prices Jump 53% In Five Years In The U.S

    Food And Drug Administration User Fee Has Been Reauthorized

    Cancer Clinical Trials Get A Brand New Platform In Melbourne

    Report Indicates UK £62bn Behind In Global R&D Investment

    Report Indicates UK £62bn Behind In Global R&D Investment

  • Manufacturing
  • Supply Chain
  • Facilities
  • Health & Nutrition
  • Events
  • Contact Us
No Result
View All Result
Pharma Advancement
No Result
View All Result
Home Drug Development Research & Development

Vyome Biosciences Presents Research Data on Development of Novel Antibiotics and Antifungal Agents to American Society of Microbiology

Yuvraj_pawp by Yuvraj_pawp
30th September 2015
in Research & Development

Vyome Biosciences, a dermatology based innovative bio-pharmaceutical company, which is pioneering the development of next generation antibiotics and antifungal agents that target antimicrobial resistance for opportunist pathogens of the skin, announced significant progress made in the development of new antibiotics to address the emerging challenges of resistance. The results, in the form of three important studies, describing its DART™ (Dual Action Rational Therapeutics) antibiotics and clinical results from its antifungal Molecular Replacement Therapy (MRT™) technology platform, were presented at the American Society of Microbiology Interscience Conference of Antimicrobial Agents and Chemotherapy (ASM- ICAAC) in San Diego, CA.

In the first study, Vyome scientists characterized the skin microbiome of acne patients where the study showed the presence of antibiotic-resistant bacteria Propionibacterium acne and Staphylococcus epidermidis in the acne lesions. The study identified the mutations that lead to resistance against the currently used antibiotics, and highlights the need to personalize acne treatment by selecting the right antibiotic to kill the bacteria. Vyome has its lead program VB1953, a novel drug targeting antibiotics resistant acne market of USD 3 Bn, for which IND (Investigational New Drug) application will be filed with the USFDA in Q4 2015.

Vyome Biosciences also presented data on a novel antibiotic based on its patented Dual Action Rational Therapeutics (DART™) technology. Compared with other antibiotics, like ciprofloxacin, DART™ antibiotics are unique in their ability to resist the development of resistance. The new antibiotic exhibits potent activity against antibiotics-resistant Propionibacterium acne and other bacteria. The scientists presented a mechanistic understanding of its unique action at the ASM-ICAAC.

“Vyome has a deep pipeline of DART™ molecules which are in pre-clinical stage. This is very interesting and creative science with far reaching benefits to address antibiotic resistance problem in the USD 50 BN antibiotic market.” said Dr. Raghunath Mashelkar, Chairman, Vyome Biosciences.

Vyome has also developed a novel antifungal agent, Procaprycin™, based on its Molecular Replacement Therapy (MRT™) platform, which replaces an essential fatty acid in the fungus and causes membrane disruption. Malassezia, a skin commensal fungus, is associated with several chronic diseases, including seborrheic dermatitis. Vyome scientists have developed MRT™ platform technology with Procaprycin™ using the functional genomic information on Malassezia. The study presented at the ASM-ICAAC meeting highlighted the mechanisms of action and recent clinical data on Procaprycin™.

“Vyome has two clinically proven products to treat seborrheic dermatitis and dandruff. This is a very novel and effective platform for antifungals and Vyome is currently pursuing commercialization discussions with partners in India and in other countries for different partnership models.” says N. Venkat, Co-founder & CEO, Vyome Biosciences.

About Vyome Biosciences Private Limited:
Vyome Biosciences is a clinical stage dermatology based biopharmaceutical company, which has novel platforms technologies and a deep pipeline of novel drugs for antibiotic resistant Acne, other opportunistic pathogens and antifungal agents. Vyome has put-together a team of scientific and management experts from India and USA to deliver company’s growth plans. Vyome is co-founded by Shiladitya Sengupta, N. Venkat, Rajesh Gokhale and Rajeev Mantri.

Contact:
N. Venkat, Co-founder & CEO
Vyome Biosciences,
Email: nvenkat@vyome.in

For more information, please contact:

Vyome Biosciences 
N Venkat
Co-founder & CEO
nvenkat@vyome.in

Perfect Relations Pvt Ltd
Premal Mandavia
Image Manager
pmandavia@perfectrelations.com

Previous Post

Eli Lilly and Company Reveals Plan for Innovation Center in Cambridge, Massachusetts

Next Post

Results of Phase 2 Study of Merck’s Investigational Beta-Lactamase Inhibitor Relebactam Presented at ICAAC/ICC 2015

Related Posts

News

Cancer Medicine Prices Jump 53% In Five Years In The U.S

3rd November 2022
Report Indicates UK £62bn Behind In Global R&D Investment
News

Report Indicates UK £62bn Behind In Global R&D Investment

3rd November 2022
News

Once More, M&As In Biotechechnology Industry Are Thriving

2nd November 2022
DNA
News

Ancient Viral DNA Guards Against Infections In Human Genome

31st October 2022
News

Omicron Subvariants Withstand Essential Antibody Treatments

31st October 2022
As Medical Uses Cope Up, Genomic Studies Reap Scale Benefits
News

Research And Development In UK Falls Behind Other Nations

28th October 2022
Next Post

Results of Phase 2 Study of Merck’s Investigational Beta-Lactamase Inhibitor Relebactam Presented at ICAAC/ICC 2015

Latest News

FDA Approvals

NHS Acquires Potentially Lifesaving Breast Cancer Medication

9th November 2022
Clinical Trials

Transfusion of The First Patients Lab-Grown Blood Cells

9th November 2022
Clinical Trials

Bispecific Cancer Drugs, Gene Therapy Advances At Next ASH

8th November 2022
India Seeks Better Pharma Market Access In The UK: Official
Facilities & Operation

India Seeks Better Pharma Market Access In The UK: Official

8th November 2022
First Virtual Drug Study Tests 2 Likely Alzheimer Therapies
Clinical Trials

First Virtual Drug Study Tests 2 Likely Alzheimer Therapies

7th November 2022
Pharma Advancement

About Us

Pharma Advancement is a leading Pharma information centric website. On one side Pharmaadvancement.com has established itself as one of the most efficient and comprehensive source of Pharma information online, dedicated to providing decision makers in all the Pharma industry sectors with reliable, accurate and useful insights into happenings in the Pharma sector.

Qucik Links

  • Drug Development
  • Manufacturing
  • News
  • Events & Conferences
  • Newsletter Archive

Resources

  • Advertise with us
  • Contact Us
  • Download Mediapack

System

  • Search
  • Sitemap
  • RSS Feed

© 2017 Copyright © Valuemediaservices 2017 All rights reserved.

No Result
View All Result
  • Home
  • Drug Development
  • Manufacturing
  • Supply Chain
  • Facilities
  • Health & Nutrition
  • Events
  • Contact Us

© 2017 Copyright © Valuemediaservices 2017 All rights reserved.

Login to your account below

Forgotten Password?

Fill the forms bellow to register

All fields are required. Log In

Retrieve your password

Please enter your username or email address to reset your password.

Log In